Adjunctive use of cenobamate for pediatric refractory focal-onset epilepsy: A single-center retrospective study

•Cenobamate is a useful adjunctive therapy for refractory focal-onset epilepsy in adult patients, but the safety and efficacy is yet to be established in the pediatric population.•We performed a retrospective analysis of a pediatric cohort of refractory focal-onset epilepsy receiving cenobamate as an adjunctive therapy.•We measured seizure reduction, median reduction in seizure frequency, median dose, responder rate, and treatment-emergent adverse events.•Cenobamate showed similar rates of efficacy, safety, and tolerability in the pediatric population when compared to adult data, even when used at maximum dose of 400 mg.